Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 24 of 24 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 S252W	gallbladder adenocarcinoma	predicted - sensitive	FGFR2 Inhibitor	Pazopanib	Case Reports/Case Series	Actionable	In a clinical case study, Votrient (pazopanib) treatment resulted in stable disease lasting over 2 years in a patient with metastatic gallbladder adenocarcinoma harboring FGFR2 S252W (PMID: 36307559).	36307559
FGFR2 S252W	adenoid cystic carcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1-3 mutations or fusions, including a partial response in a patient with adenoid cystic carcinoma of the submandibular gland harboring FGFR2 S252W (PMID: 38603650; NCT02465060).	38603650
FGFR2 S252W	endometrial cancer	sensitive	FGFR2 Inhibitor	Zoligratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980).	25169980
FGFR2 S252W	endometrial carcinoma	sensitive		GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (95% vs 30%) in cell line xenograft models of endometrial carcinoma harboring FGFR2 S252W compared to FGFR2 wild-type models (PMID: 23536011).	23536011
FGFR2 S252W	endometrial carcinoma	decreased response		RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased response to RO4987655 in culture (PMID: 26438159).	26438159
FGFR2 S252W	endometrial carcinoma	decreased response		Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR2 S252W	endometrial carcinoma	sensitive		RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of endometrial carcinoma cells harboring FGFR2 S252W in culture (PMID: 26438159).	26438159
FGFR2 S252W	endometrial cancer	decreased response	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).	26294741
FGFR2 S252W	endometrial cancer	sensitive	FGFR2 Inhibitor	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 S252W (PMID: 18552176) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).	18552176 27535969
FGFR2 S252W	endometrial cancer	sensitive	FGFR2 Inhibitor	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 27627808).	27627808
FGFR2 S252W	Advanced Solid Tumor	conflicting	FGFR Inhibitor (Pan)	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 S252W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 S252W	endometrial cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lytgobi (futibatinib) treatment led to inhibition of cell proliferation in an endometrial cancer cell line harboring FGFR2 S252W in culture (PMID: 32973082).	32973082
FGFR2 S252W	Advanced Solid Tumor	conflicting	FGFR Inhibitor (Pan)	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2 S252W	endometrial cancer	sensitive	FGFR Inhibitor (Pan)	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and cell proliferation in endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR2 S252W	endometrial cancer	sensitive		Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR2 S252W	endometrial cancer	sensitive		Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR2 S252W	endometrial cancer	sensitive	FGFR Inhibitor (Pan)	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (Nintedanib) inhibited cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).	22238366
FGFR2 S252W	endometrial cancer	decreased response	FGFR Inhibitor (Pan)	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) did not potently inhibit cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).	22238366

Showing 1 to 24 of 24 entries

Filter rows:

Profile Name	FGFR2 S252W
Gene Variant Detail	FGFR2 S252W (gain of function - predicted)
Relevant Treatment Approaches	FGFR Inhibitor (Pan) FGFR2 Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting